Field Clinical Specialist/Engineer

Imaging collaboration aims to improve brain-computer interfaces. Paradromics, Siemens Healthineers build imaging workflow for brain implants Staff Informa Markets Engineering October 19, 2026 Advanced 3T MRI systems from Siemens Healthineers, such as MAGNETOM Cima.X, have the potential to support the growing clinical use of implantable brain-computer interfaces (BCIs). Paradromics is in collaboration with Siemens Healthineers to develop an advanced multimodal imaging platform designed to support the growing clinical use of implantable brain-computer interfaces (BCIs). The companies will develop an integrated imaging approach spanning the continuum of BCI care, from patient candidacy assessment and neural target identification through surgical planning, intraoperative navigation, post-implant localization, neural validation of functional imaging findings, and outcomes assessment. A new imaging workflow for BCI care The collaboration comes at a time when brain-computer interfaces are advancing from academic proof-of-concept research toward clinical systems capable of restoring functions such as communication and computer control. As these systems become more sophisticated, accurately identifying the areas of the brain responsible for speech, movement, and other functions becomes increasingly important to device performance and patient outcomes. "Building the best hardware is only part of the story. BCI performance begins before an implant ever reaches the brain," said Matt Angle, PhD, founder and CEO of Paradromics. "The ability to understand each patient's individual anatomy and functional organization can help us identify the right neural target and place our technology with greater accuracy. Working with Siemens Healthineers will help us streamline this process prior to surgery, so that patients get the best possible outcome." Multimodal imaging meets clinical precision The planned workflow will integrate multiple imaging modalities, including structural MRI, functional MRI, vascular imaging, and CT. Together, these technologies can help clinical teams assess brain anatomy, identify functionally relevant regions, plan surgical trajectories, avoid critical vascular structures, and determine the final location of implanted BCI components. End-to-end imaging workflows will also be developed in cooperation with Paradromics clinical research investigators, including Daniel B. Rubin, MD, PhD, of the Mass General Brigham Neuroscience Institute's Center for Neurotechnology and Neurorecovery. The participation of leading clinical research centers will help ensure the workflow is informed by real-world BCI research and clinical practice as it is refined for broader adoption. "At Siemens Healthineers, we are focused on pioneering breakthroughs in healthcare by transforming imaging into increasingly precise, actionable information for clinicians," said Dr. Donald Hardie, head of Magnetic Resonance at Siemens Healthineers. "Brain-computer interfaces represent an important new frontier for neuroscience. Working with Paradromics gives us the opportunity to explore how advanced multimodal imaging, automation and clinical decision support can help make these procedures more precise, repeatable and ultimately more accessible across leading medical centers." A distinctive element of the collaboration will be the ability to compare functional imaging predictions with neural activity recorded directly from implanted Paradromics devices. Intracortical recordings can provide high-resolution information about the activity of individual neurons and their usefulness for decoding intended speech or movement. Comparing those signals with preoperative imaging could help researchers determine how accurately imaging identifies functionally important brain regions and continually refine imaging and targeting methods for future patients. "Our approach has always been to build the Connexus BCI platform into the existing healthcare ecosystem, working with leaders across the care pathway and using established technologies and clinical workflows wherever they make sense," said William J. Marks, Jr., MD, MS-HCM, Chief Clinical Officer of Paradromics. "We want to make things easy for hospitals, not require them to buy and train on bespoke capital equipment. Siemens Healthineers is the leader in advanced medical imaging, and most hospitals in the US use their systems. This is an obvious opportunity for collaboration." From speech restoration to broader applications The collaboration is expected to initially focus on speech-motor function, building on Paradromics' clinical work in communication restoration. The companies envision extending the approach to additional BCI applications, including hand motor control and language restoration following stroke. Imaging and targeting techniques developed for speech, motor and language applications may also have relevance to visual, auditory and cognitive mapping, as well as broader neurosurgical planning. Informa Markets Engineering Want more MD+DI in your search results?

Paradromics gets FDA nod for broader BCI device compatibility. The FDA approval will enable the BCI platform to support more internet-connected personal devices including laptops, tablets and phones. Neurotech company Paradromics has received approval from the US Food and Drug Administration (FDA) to broaden the range of personal computing devices compatible with its investigational brain-computer interface (BCI) system. The authorisation pertains to the company's ongoing Connect-One Early Feasibility Study, which is evaluating the safety and functionality of the Connexus BCI for restoring communication and enabling computer-device control in individuals with severe motor impairment. The FDA approval will enable the BCI platform to support a wider variety of internet-connected personal devices including laptops, tablets and mobile phones. Paradromics intends to implement these changes through its Convey user interface, which is designed to translate decoded neural signals into communication and digital control across supported platforms. Previously, the BCI system was limited to use with company-provided hardware. The approval marks what Paradromics describes as a step towards allowing users with severe motor impairment to interact with the types of devices they use in everyday life. Once Paradromics completes the agreed deployment and testing process, new compatible personal devices could be added without requiring separate approvals for each device. The company stated that this change does not affect the existing clinical care model in the study but offers greater flexibility to assess how BCI-enabled computer control might fit into individual daily digital environments. Paradromics founder and CEO Matt Angle said: "As Medical Device Network think about building BCI as a technology platform, Medical Device Network need to push for generalised connectivity. "That means being able to connect with the products and technology that are already part of your life. This approval begins clearing the way toward a BCI platform that can move with the user rather than tethering him or her to a fixed computing environment." Paradromics is developing its BCI platform to decode neural activity recorded at the level of single neurons, with initial studies focused on restoring communication for people unable to speak due to paralysis and severe motor impairments. The company's stated long-term strategy aims to enable the translation of neural intent into actions across an expanding range of technologies and applications. In March this year, Paradromics initiated a programme to drive academia's access to its BCI to advance innovation in the device space. Give your business an edge with its leading industry insights.